Pennsylvania is currently home to 3311 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768
Recruiting
The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric and adult participants who have cholestatic liver disease with pruritus that has been refractory to other therapies, and who have no other treatment options.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
05/30/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Cholestatic Liver Disease (except ALGS, PFIC, PBC and PSC)
Register for Updates
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613
Recruiting
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a humanized T cell engaging bispecific antibody targeting CLDN6, in subjects with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Context Investigational Site, Philadelphia, Pennsylvania
Conditions: Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Register for Updates
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
NCT06463028
Recruiting
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Alliance Cancer Specialists, PC, Doylestown, Pennsylvania
Conditions: Endometrial Cancer
Register for Updates
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285
Recruiting
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Alliance Cancer Specialists, Horsham, Pennsylvania
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
Register for Updates
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
05/30/2025
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effective oral Upadacitinib is in treating moderately to severely active Crohn's Disease in pediatric participants aged 2 to 18 years old who have had inadequate response, loss of response, intolerance, or... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/30/2025
Locations: Children's Hospital of Philadelphia - Main /ID# 262197, Philadelphia, Pennsylvania
Conditions: Crohn's Disease
Register for Updates
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622
Recruiting
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550 (study 1305-0014 or 1305-0023). The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until sympto... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Register for Updates
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748
Recruiting
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Alliance Cancer Specialists, Bensalem, Pennsylvania
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Register for Updates
Synovial Sarcoma Registry / Biospecimen Repository
NCT05910307
Recruiting
The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing. Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updat... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Synovial Sarcoma
Register for Updates
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
NCT05881408
Recruiting
The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is a randomized, double-blind, placebo-controlled 2-part study. Participants will be in the study for approximately 128 weeks. All participants will have the opportunity to receive intravenous (IV) delandistrogene moxeparvovec in either Part 1 or Part 2.
Gender:
MALE
Ages:
All
Trial Updated:
05/30/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Duchenne Muscular Dystrophy
Register for Updates
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/30/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Primary Generalized Tonic-Clonic Seizures
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264
Recruiting
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/30/2025
Locations: Univ of Pennsylvania Med Ctr, Philadelphia, Pennsylvania
Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Register for Updates